MASLD Management: Medications & Monitoring | June 12, 2025
Date of Presentation: June 12, 2025
Type: Past Presentation
Audience: Clinical
Program: Diabetes
Keywords: #disease #fatty #liver #MASLD #metabolic #nonalcoholic #steatotitic
In this presentation, Dr. Greenlee provides a comprehensive overview of medications and monitoring of MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), highlighting GLP-1/Dual RAs and pioglitazone for their liver and cardiovascular benefits, safe use in compensated cirrhosis, and the importance of continued statin therapy. Dr. Greenlee also addresses fibrosis risk screening, emerging therapies like resmetirom, and the role of metabolic surgery.
Presented by:
Dr. Mary Carol Greenlee
Faculty
Mary Carol Greenlee, MD, MACP, is board certified in internal medicine and in endocrinology, diabetes, and metabolism with over 30 years’ experience in private practice. Dr. Greenlee graduated Summa Cum Laude from Miami University (Ohio) and with Highest Distinction from Indiana University School of Medicine. She did her internal medicine internship and residency at Ball Memorial Hospital in Muncie, IN before returning to IU Medical Center for her fellowship in endocrinology. Carol chaired the “AID” project to develop shared decision-making tools for insulin therapy, as well as several workgroups focused on improving care coordination between primary and specialty care. She received NCQA recognition for Patient-Centered Specialty Care in 2014 and the Endocrine Society award for Outstanding Clinical Practitioner in 2016.
Read the full bio …Resources Provided:
Date added: June 13, 2025











































